Atrial fibrillation is the most common irregular heart rhythm that starts in the atria. While it is often a mere annoyance, it can also be responsible for life-threatening medical emergencies that result in cardiac arrest, stroke and sudden death. Take advantage of this rare opportunity to chat live on October 28 with atrial fibrillation experts …
Read More
While the Atrial Fibrillation Resolution will make a difference in our knowledge and understanding of afib, there is so much more that we can do. My dream is that, by aggregating lots of data (not individually identifiable) from those with afib across the world, we can identify clusters of things that individual doctors may not …
Read More
Raising afib awareness is intensely personal for StopAfib.org founder, Mellanie True Hills, and led her to create the first Atrial Fibrillation Awareness Month in 2007. Working with other organizations, Hills helped urge the U.S. Senate to officially designate National Atrial Fibrillation Awareness Month in September 2009. This roundup recaps what happened during Afib Month 2011, …
Read More
September is Atrial Fibrillation Awareness Month. Lots of folks don’t know too much about the condition, which is an irregular heart beat that can lead to serious complications such as dementia, heart failure, stroke or even death. To help spread the word, StopAfib.org presents these 10 afib facts and figures that will probably surprise even …
Read More
By Mellanie True Hills September is Atrial Fibrillation Awareness Month. A lot of folks may ask: Why do we need a month devoted to afib? Or, even, what is atrial fibrillation, anyway? Afib is an irregular heart beat that can lead to serious complications, such as dementia, heart failure, stroke, or even death. Too many …
Read More
The US Food & Drug Administration (FDA) Advisory Committee just voted 9-2, with 1 abstaining, to recommend that the FDA approve rivaroxaban (Xarelto) for prevention of atrial fibrillation strokes. See our full story, now up at: FDA Panel Votes for Rivaroxaban: Atrial Fibrillation Patients May Soon Have Two Alternatives to Warfarin for Stroke Prevention
Read More
StopAfib.org is among a group of experts calling today for urgent action to prevent an atrial fibrillation stroke crisis in Latin America. Action for Stroke Prevention, a group of health experts from across the globe, is launching a new report, How Can We Avoid a Stroke Crisis in Latin America?, at the International Society for …
Read More
Our September EP Lab Digest Patient Perspective column, Stopping Atrial Fibrillation is Big News!, focuses on activities taking place during Atrial Fibrillation Awareness Month, including public service announcements featuring daytime TV star Susan Lucci and former NBA player and general manager Jerry West. It also talks about how Atrial Fibrillation Month came into being. To …
Read More
Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn …
Read More
A brand new tool, Atrial Fibrillation in Primary Care (AFIP), was just released at the European Society of Cardiology meeting in Paris. This tool may be useful for afib patients and their caregivers, especially those who are newly-diagnosed with atrial fibrillation, in working with doctors. Two members of the StopAfib.org Global Medical Advisory Board are …
Read More